

Saskatchewan Immunization Manual Amendments November 2015

Instructions: Please remove and discard the corresponding pages in each chapter section and insert the amended pages as noted below in each corresponding chapter section dated **November 2015**.

Chapter 7 Immunization of Special Populations

- TOC page 2 (January 2015)
 - Under section 9.0 Appendices, Appendix 7.7 Tdap Immunization Decision Chart for Pregnant Women is new.
- P. 16 (May 2015) 3.3A: Publicly Funded Vaccines and Immune Globulins – Human Immunodeficiency Virus
 - New footnote #4 added: “Infectious disease physicians may recommend additional vaccines such as Meningococcal B for infants/children born to HIV infected mothers. In these situations, follow the vaccine scheduling in SIM chapter 10 unless otherwise directed by the ID physician”.
- P. 23 (January 2015) 5.2.A: Publicly Funded Vaccines – Pregnancy
 - Revised bullets pertaining to Tdap administration during pregnancy:
 - Pregnant women who have not received a pertussis-containing vaccine dose in adulthood (≥ 18 years old) should be offered Tdap at or after 26 weeks gestation.
 - In an outbreak situation, pregnant women who are ≥ 26 weeks gestation should be offered Tdap vaccination regardless of their pertussis immunization history, based on recommendations from the regional Medical Health Officer. This Tdap dose should be given regardless of whether or when a pregnant woman has received Tdap in the past (e.g., as their adolescent dose; as their adult booster; as a healthcare worker; as a previous post-partum cocooning dose; or a dose during a previous pregnancy).
 - If Tdap is administered to a pregnant woman **before** 26 weeks gestation, **it should not be repeated after 26 weeks gestation or post-delivery**.
 - Offer 1 dose of Tdap post-natally to women who have not previously received an adult dose of Tdap. Women who previously received Tdap anytime as an adult or during their current pregnancy do not require Tdap post-delivery.
- **New!** P. 40 Appendix 7.7: Tdap Immunization Decision Chart for Pregnant Women
 - **Please ensure all staff review this chart.**

Chapter 10 Biological Products

- TOC (first page dated April 2015)
 - Zostavax removed as no longer available in Canada.
 - BCG vaccine removed as no longer available in Canada.
- TOC (third page dated April 2014)
 - Tick Borne Encephalitis vaccines removed as no longer licensed in Canada.
- Updated product monograph links for:
HIBERIX Avaxim Engerix B Zostavax II IMOGAM Rabies
- INFANRIX™-IPV (January 2015)
 - Updated product monograph link.
 - Vaccine components updated.
 - New statement re: stopper: “The vial is sealed with a butyl rubber stopper. The syringes are presented with or without needles and fitted with butyl rubber plunger stoppers and tip caps or rubber shields”.

Saskatchewan Immunization Manual Amendments November 2015

- ROTARIX (April 2014 pp. 1-2)
 - New 2015 product monograph link.
 - Vaccine components – Revised last sentence: “The plunger stopper contains butyl rubber”.
- Adacel (January 2015) and Boostrix (January 2015)
 - **New** indication and footnote added to align with recommendations in Chapter 7:
 - **11.** Pregnant women who: have not previously received Tdap as an adult; or who live in an area where a pertussis outbreak has been declared.⁷
 - ⁷ Refer to Chapter 7 *Appendix 7.7: Tdap Immunization Decision Chart for Pregnant Women*
- Varilrix and Varivax (both dated Sept, 2015, both pages 1 of 2)
 - Date correction under indication #1 is 1993, not 2003.
- VariZIG (August 2015, pp. 1-2)
 - VariZig Sterile Liquid is a new formulation added to page info.
 - Component section now specific to powder and liquid formulations.
- BCG and Tick Borne Encephalitis vaccines removed as no longer licensed in Canada. Please remove these pages from print version of the SIM.